Search Results
Eunice Wang, MD, shares exciting data for acute myeloid leukemia (AML) presented at ASH 2017
Searching for Effective Treatment in Newly Diagnosed FLT3 Positive AML | Eunice Wang | ASH 2021 #AML
Eunice Wang, MD, on how minimal residual disease is being integrated into treatment decisions in AML
Eunice Wang, MD, on strategies for frail AML patients who do not qualify for intensive therapy
Eunice Wang, MD, on incorporating Vyxeos (liposomal daunorubicin and cytarabine) in AML treatment
Eunice Wang, MD, on exciting news stemming from this year’s ASH meeting in the treatment for ALL
Eunice Wang, MD, shares what we've learned about gilteritinib since the 2017 ASCO Annual Meeting
Eunice Wang, MD, considers approaches for clinicians when managing frail AML patients
Dr. Wang on Results With Crenolanib Plus Chemotherapy in AML
Targeted Therapy for Acute Myeloid Leukemia
Acute Myeloid Leukemia: Understanding Biologic Drivers
Eunice S. Wang, MD, on immunotherapy and its potential role in treating hematological malignancies
